ライフサイエンスコーパス: transplant donor

1 patients lacking a suitable bone marrow (BM) transplant donor.

2 d donor lymphocyte infusions (DLIs) from the transplant donor.

3 tes, higher body mass index, and a cadaveric transplant donor.

4 om 11 coronary artery disease patients and 1 transplant donor.

5 atients and their HLA-C-mismatched unrelated transplant donors.

6 of sepsis patients vs cancer patients and vs transplant donors.

7 uring the risk evaluation of potential renal transplant donors.

8 e general safety of this approach for normal transplant donors.

9 osis, and evaluation of living-related liver transplant donors.

10 HGF) mobilize potential tolerogenic cells in transplant donors.

11 tured aortic ECs derived from multiple heart transplant donors.

12 cines could be used either in patients or in transplant donors.

13 promoter (Flk-1/LZ or Tie-2/LZ) were used as transplant donors.

14 able with prior data for normal human kidney transplant donors.

15 of renal disease, including potential kidney transplant donors.

16 ick figure field counseling for living renal transplant donors accurately provides information to bot

17 sely affecting survival included the year of transplant, donor age, and donor-recipient gender mismat

18 on land mass, population, livers discarded, transplanted, donor age, or recipient MELD scores.

19 r 2002, 2,597 primary cadaveric kidney-alone transplants (donor age 5-45 years, recipient age 2-20 ye

20 lished that a mismatch for MICA A5.1 between transplant donor and recipient is critical for BKPyV rea

21 ially involved in overlapping care of the HC transplant donor and the recipient.

22 We genotyped 435 pancreas transplant donors and 431 recipients who had undergone p

23 positivity in the absence of HBsAg in organ transplant donors and in candidate patients for chemothe

24 was sought in an independent group of kidney transplant donors and recipients from Dublin, Ireland us

25 quences of tobacco smoke exposure in cardiac transplant donors and recipients with an emphasis on all

26 pulations of racially and ethnically diverse transplant donors and recipients.

27 aluated among 4 groups: 7/8 bidirectional MM transplants (donor and recipient heterozygous MM, n = 13

28 ne system was tolerant to host, mESC, and BM transplant donor antigens.

29 EC cultures prospectively isolated from the transplant donor at the time of transplantation.

30 ategy to prime HA-1- or HA-2-specific CTL in transplant donors before adoptive transfer.

31 h persistent chimerism preferentially in the transplanted donor bone.

32 One hundred eight healthy liver transplant donor candidates were examined with two MR ch

33 eath (AICD) of anti-recipient T cells within transplant donor cell populations, with the goal of redu

34 d knowledge of the phenotype and function of transplanted donor cells facilitate strategies to optimi

35 most common bacterial causes of solid-organ transplant donor-derived infection reported in transplan

36 hibit little or no antibody specific for the transplant donor during the early weeks and months after

37 Living kidney transplant donors generally have a favorable renal funct

38 A severe shortage of human transplant donors has sparked interest in the use of ani

39 he preoperative screening of potential renal transplant donors has undergone a major evolution with t

40 ns of leukocytes collected from the original transplant donor have been used to induce a direct graft

41 entration, and compared with myocardium from transplant donor hearts.

42 ed tumors are de novo tumors that develop in transplanted donor hematogenous or lymphoid cells after

43 a direct relationship between the number of transplanted donor HLA-A2-expressing cells and the perce

44 suggested that host HSCs can be replaced by transplanted donor HSCs, even in the absence of cytoredu

45 ndogenous HSCs and facilitate engraftment of transplanted donor HSCs.

46 l and thus prevent productive engraftment of transplanted donor HSCs.

47 Recognition that transplanted donor immune cells can cure patients with l

48 LAM cells arise from the patient or the lung transplant donor is an area of controversy.

49 (steroid, i.e., the "T4 Protocol") in organ transplant donors, is becoming increasingly used.

50 , when lower doses (50 or 25) of islets were transplanted, donor islets in the pancreas were much mor

51 For example, transplanting donor kidneys > or =55 yr old into recipie

52 Fifteen transplant donor livers served as controls.

53 seen (3.2%) in sections from a truly normal transplant donor lung.

54 Transplanted donor lymphocytes infused during hematopoie

55 tokines can stimulate the differentiation of transplanted donor marrow cells into the osteopoietic li

56 tes that B cells respond specifically to the transplant donor more often than previously thought.

57 e genotyped donors managed by the California Transplant Donor Network from 2001 to 2008 for the 4G/5G

58 ntial organ donors managed by the California Transplant Donor Network from 2001 to 2008.

59 ntial organ donors managed by the California Transplant Donor Network from 2002 to 2007.

60 Patients received DLI from their original transplant donors on a bulk-dose (n = 34) or on an escal

61 a; control lungs (n = 20) were obtained from transplant donors or from lung cancer resections.

62 This would establish the theoretical risk of transplanting donor organs from a patient with a known r

63 4 beta 1 in vivo interaction to increase the transplant donor pool through modulation of marginal ste

64 Transplanted donor pre-pDCs expanded in vivo for 2 weeks

65 CA) in BKPyV reactivation in a cohort of 144 transplant donor/recipient pairs, including recipients w

66 -mismatched healthy volunteers and prekidney transplant donor/recipient pairs.

67 ion in GVHD was associated with expansion of transplanted donor regulatory T cells and with tissue-sp

68 ailed imatinib but has a possible allogeneic transplant donor, should one offer dasatinib or nilotini

69 Postkidney transplant donor-specific antibodies (DSA) have been ide

70 ant sera, and they were associated with post-transplant donor-specific HLA antibodies, antibody-media

71 atherosclerosis is supported by necropsy and transplant donor studies.

72 sease (GVHD) is a T-cell-mediated disease of transplanted donor T cells recognizing host alloantigens

73 plays a role in the homeostatic survival of transplanted donor T cells.

74 to induce tolerance to kidney allografts by transplanting donor thymic grafts simultaneously with th

75 In rodent models, investigators have transplanted donor tracheas into a recipient rat's abdom

76 Sex, ischemia time, race, previous transplant, donor type, nephrectomy technique, and stent

77 Mixed chimeras accepted subsequently transplanted donor-type rat hearts (>100 days) without i

78 fic CD8+ T cells from the blood of stem cell transplant donors using staining with HLA-peptide tetram

79 kappa GFR values obtained in potential renal transplant donors versus frequencies indicates a mean va

80 The transplant donor was an HLA-identical sibling (n = 35) o

81 on, the renal function of 80 potential renal transplant donors was measured using only external radia

82 In murine models, treatment of transplant donors with human AAT resulted in an increase

83 we investigated the effect of pretreating BM transplant donors with IL-18 on the severity of acute GV

84 Pretreatment of allogeneic BM transplant donors with IL-18 significantly improved surv

85 sparing the GVL, based on oral treatment of transplant donors with recipient Ags, associated with th